Skip to main content

A recent trial revealed promising results using traditional Qiliqiangxin, in the treatment of heart failure


A recent placebo-controlled trial presented at the European Society of Cardiology (ESC) 2023 Congress has revealed promising results regarding the use of a traditional Chinese herbal remedy, Qiliqiangxin, in the treatment of heart failure with reduced ejection fraction (HFrEF). HFrEF is a condition where the heart's left ventricle loses its ability to contract effectively, leading to insufficient blood circulation.

The study, known as QUEST, involved over 3,000 HFrEF patients who were randomly assigned to take Qiliqiangxin or a placebo in addition to their standard triple-therapy regimen for heart failure. Qiliqiangxin, composed of 11 plant-based ingredients known for their diuretic and cardiotonic effects, demonstrated a significant reduction in the risk of cardiovascular death and hospitalization due to heart failure by more than 20%. This reduction was consistent across various patient groups.

While these findings are promising, some questions remain, including the limited enrollment of patients taking other standard heart failure medications like SGLT-2 inhibitors. Nevertheless, the study suggests that Qiliqiangxin may offer a valuable addition to heart failure treatment options, particularly for patients who cannot tolerate certain components of standard therapy.

The capsules were well-tolerated with no major differences in adverse events between the Qiliqiangxin group and the placebo group. However, the regimen of four Qiliqiangxin capsules three times a day may pose challenges for some patients. Researchers also noted the need to further investigate the specific active ingredients in Qiliqiangxin and the standardization of herbal products.

In conclusion, this study offers hope for individuals with HFrEF and highlights the potential of traditional Chinese medicine in modern healthcare, though further research is needed to fully understand its benefits and mechanisms of action. Go to Medium Article

Comments

Popular posts from this blog

Light Therapy holds promise as a treatment for Alzheimer's Disease

A new article, conducted by Lili Zang and colleagues from Weifang Medical University School of Nursing in Shandong Province, China, discusses a meta-analysis of 15 high-quality trials that investigated the impact of light therapy on individuals with Alzheimer’s disease (AD). The meta-analysis included 598 patients with mild to moderate Alzheimer’s disease, and it covered 15 randomized controlled trials conducted in seven different countries. Those trials were published between 2005 and 2022. Sleep Improvement Light therapy led to significant improvements in several sleep measures. It notably enhanced sleep efficiency, increased interdaily stability, and reduced intradaily variability, all of which are indicators of better sleep quality. Light therapy was associated with a reduction in agitation, depression, and caregiver burden among individuals with Alzheimer’s disease. A significant advantage over usual care was shown in reducing the severity of psychobehavioral symptoms, as assessed...

Los no fumadores engordan menos

Un nuevo estudio relaciona el tabaquismo con la ganancia de peso, y concluye que las personas fumadoras activas, no sólo las que lo dejan, engordan más que las no fumadoras. Después de cuatro años de análisis en la Universidad de Navarra, las personas que menos engordaron fueron las que nunca habían fumado.

Lacticaseibacillus rhamnosus may help in periodontal disease

A new study explores how a specific probiotic, Lacticaseibacillus rhamnosus GG (LGG), might help improve the regeneration of bones in the gums affected by periodontal disease, especially in the presence of high cholesterol levels (hyperlipidemia).  Periodontal disease can lead to the loss of bone in the jaw, making it challenging for the bone to regenerate. The researchers used a rat model with conditions mimicking periodontal disease, high cholesterol, and a defect in the gums. The rats were given LGG for six weeks, and then various measurements were taken after sacrificing the rats to understand the effects. They found that the bone density, volume, and thickness in the affected area increased after the rats were given LGG.  Interestingly, these improvements were not due to direct effects on the oral bacteria but were linked to changes in the gut microbiota.  When fecal matter containing the altered gut bacteria from LGG-treated rats was transplanted into other rats, si...